Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation

Pharmaceutical Research

Volumn 24, Issue 12, 2007, Pages 2239-2248

  Vlugt Wensink, K D F ^a,b   De Vrueh, R ^a   Gresnigt, M G ^c   Hoogerbrugge, C M ^c   Van Buul Offers, S C ^c   De Leede, L G J ^a   Sterkman, L G W ^a   Crommelin, D J A ^a,b   Hennink, W E ^b   Verrijk, R ^a  

^a OctoPlus NV   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

dex HEMA microspheres; Dextran; hGH; In vitro in vivo correlation

Indexed keywords

BIOLOGICAL MARKER; DEXTRAN; HUMAN GROWTH HORMONE; METHACRYLIC ACID DERIVATIVE; MICROSPHERE; NITROGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BODY HEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; GEL PERMEATION CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; KINETICS; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

AGED; ANIMALS; BIOLOGICAL MARKERS; BODY SIZE; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DEXTRANS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMPOUNDING; DWARFISM; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; METHACRYLATES; MICE; MICE, MUTANT STRAINS; MICROSPHERES; MIDDLE AGED; MODELS, BIOLOGICAL; PARTICLE SIZE; SOLUBILITY; TRANSCRIPTION FACTOR PIT-1;

EID: 35848940494     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9433-y     Document Type: Article

References (46)

1. J. L. Cleland, E. Duenas, A. Daugherty, A. Marian, J. Yang, M. Wilson, A. C. Celniker, A. Shahzamani, V. Quarmby, H. Chu, V. Mukku, A. Mac, M. Roussakis, N. Gillette, B. Brooks, D. Yueng, D. Brooks, Y.-F. Maa, C. Hsu, and J. S. Jones. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide long lasting effect. J. Control. Rel. 49:193-205 (1997).
2. O. L. Johnson, J. L. Cleland, H. J. Lee, M. Charnis, E. Duenas, W. Jaworowicz, D. Shepard, A. Shahzamani, A. J. S. Jones, and S. D. Putney. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 2:795-799 (1996).
3. M. Katakam, W. R. Ravis, and A. K. Banga. Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J. Control. Rel. 49:21-26 (1997).
4. M. Reslow, M. Joensson, and T. Laakso. Sustained-release of human growth hormone from PLG-coated starch microspheres. Drug Del. Sys. Sci. 2:103-109 (2002).
5. S. Takada, Y. Yamagata, M. Misaki, K. Taira, and T. Kurokawa. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J. Control. Release 88:229-242 (2003).
6. P. Van de Wetering, A. T. Metters, R. G. Schoenmakers, and J. A. Hubble. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. J. Control. Rel. 102:619-627 (2005).
7. E. O. Reiter, K. M. Attie, T. Moshang, B. L. Silverman, S. F. Kemp, R. B. Neuwirth, K. M. Ford, and P. Saenger. A multicenter study of the efficacy and safety of sustained-release growth hormone in the treatment of naive pediatric patients with growth hormone deficiency. J. Clin. Endocrinol. Metab. 86:4700-4706 (2001).
8. B. L. Silverman, S. L. Blethen, E. O. Reiter, K. M. Attie, R. B. Neuwirth, and K. M. Ford. A long-acting human growth hormone (Nutropin DepotR): efficacy and safety following two years of treatment in children with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 15:715-722 (2002).
9. K. Fu, C. Pack, A. M. Klibanov, and R. Langer. Visual evidence of acidic environment within degrading pol(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17:100-106 (2000).
10. W. Lu and T. G. Park. Protein release from poly(lactic-co-glycolic acid) microspheres: protein stability problems. PDA J. Pharm. Sci. Tech. 49:13-19 (1995).
11. S. P. Schwendeman. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 19:73-98 (2002).
12. M. Van de Weert, W. E. Hennink, and W. Jiskoot. Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles. Pharm. Res. 17:1159-1167 (2000).
13. S. Hermeling, D. J. A. Crommelin, H. Schellekens, and W. Jiskoot. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21:897-903 (2004).
14. W. V. Moore and P. Leppert. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51:691-697 (1980).
15. R. Langer and N. A. Peppas. Advances in biomaterials, drug delivery, and bionanotechnology. AICHe J. 49:2990-3006 (2003).
16. N. A. Peppas, P. Bures, W. Leobandung, and H. Ichikawa. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50:27-46 (2000).
17. W. N. E. Van Dijk-Wolthuis, S. K. Y. Tsang, J. J. Kettenes-van den Bosch, and W. E. Hennink. A new class of polymerizable dextrans with hydrolyzable groups: Hydroxyethyl methacrylated dextran with and without oligolactate spacer. Polymer 38:6235-6242 (1997).
18. O. Franssen, L. Vandervennet, P. Roders, and W. E. Hennink. Chemically degrading dextran hydogels: controlled release of a model protein from cylinders and microspheres. J. Control. Rel. 60:211-221 (1999).
19. J. A. Cadée, C. J. de Groot, W. Jiskoot, W. den Otter, and W. E. Hennink. Release of recombinant human interleukin-2 from dextran-based hydrogels. J. Control. Rel. 78:1-13 (2002).
20. J. A. Cadée Brouwer, W. den Otter, W. E. Hennink, and M. J. A. van Luyn. A comparative biocompatibility study of microspheres based on crosslinked dextran or poly(lactic-co-glycolic)acid after subcutaneous injection in rats. J. Biomed. Mater. Res. 56:600-609 (2001).
21. R. J. H. Stenekes, O. Franssen, E. M. G. van Bommel, D. J. A. Crommelin, and W. E. Hennink. The preparation of dextran microspheres in an all-aqueous system: Effect of the formulation parameters on particle characteristics. Pharm. Res. 15:557-561 (1998).
22. R. J. H. Stenekes and W. E. Hennink. Equilibrium water content of microspheres based on cross-linked dextran. Int. J. Pharm. 189:131-135 (1999).
23. R. J. H. Stenekes, S. C. De Smedt, J. Demeester, G. Sun, Z. Zhang, and W. E. Hennink. Pore sizes in hydrated dextran microspheres. Biomacromol. 1:696-703 (2000).
24. R. J. H. Stenekes and W. E. Hennink. Polymerization kinetics of dextran-bound methacrylate in an aqeous two-phase system. Polymer 41:5563-5569 (2000).
25. J. T. Chung, K. D. F. Vlugt-Wensink, W. E. Hennink, and Z. Zhang. Effect of polymerization conditions on the network properties of dex-HEMA microspheres and macro-hydrogels. Int. J. Pharm. 288:51-61 (2005).
26. K. D. F. Vlugt-Wensink, T. J. H. Vlugt, W. Jiskoot, D. J. A. Crommelin, R. Verrijk, and W. E. Hennink. Modelling the release of proteins from degrading dex-HEMA microspheres using kinetic Monte Carlo simulations. J. Control. Rel. 111:117-127 (2005).
27. K. D. F. Vlugt-Wensink, Y. M. Meijer, M. van Steenbergen, R. Verrijk, W. Jiskoot, D. J. A. Crommelin, and W. E. Hennink. Effect of excipients on the encapsulation efficiency and release of human growth hormone from dextran microspheres. Eur. J. Pharm. Biopharm. DOI 10.1016/j.ejpb.2007.04.11 (2007).
28. E. Y. Chen, Y. C. Liao, D. H. Smith, H. A. Barrera-Saldana, R. E. Gelinas, and P. H. Seeburg. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics 4:479-497 (1989).
29. S. C. Van Buul-Offers, I. Ueda, and J. L. Van den Brande. Biosynthetic somatomedin C (SM-C/IGFI) increases the length and weight of Snell dwarf mice. Pediatr. Res. 20:825-827 (1986).
30. P. C. R. Hughes and J. M. Tanner. A longitudinal study of the growth of the black-hooded rat: methods of measurement and rates of growth for skull, limbs, pelvis, nose-rump and tail lengths. J. Anat. 106:349-370 (1970).
31. P. R. P. Salacinski, C. McLean, J. E. C. Sykjes, V. Clement-Josnes, and P. J. Lowrly. Iodination of proteins, glycoproteins and peptides using a solid phase iodinizing agent, 1,3,4,6-tertachloro-3 a, 6 a-diphenyl glycoluril (iodogen). Anal. Biochem. 117:136-146 (1981).adioreceptor assay.
32. L. S. Haro and F. J. Talamantes. Secreted mouse prolactin (prolactin) and stored ovine prolactin. II. Tole of amides in receptor binding and immunoreactivity. Endocrinology 116:353-358 (1985b).
33. K. Goji. Pulsatile characteristics of spontaneous growth hormone (GH) concventration profiles in boys evaluated by an ultrasensitive immonoradiometric assay: evidence for ultradian periodicity of GH secretion. J. Clin. Endocrinol. Metab. 76:667-670 (1993).
34. M. Rowland and T. N. Tozer. (eds.), Balado D. Clinical pharmacokinetics; concepts and applications. London: Lea & Febiger books, pp. 35-50 (1995).
35. O. J. Jorgensen. Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr. Rev. 12:189-207 (1991).
36. T. Laursen, J. Moller, J. O. Jorgensen, H. Orskow, and J. S. Christiansen. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin. Endocrinol. 45:333-339 (1996).
37. T. C. Laurent. The Interaction between polysaccharides and other macromolecules. The solubility of proteins in the presence of dextran. Biochem. J. 89:253-257 (1963b).
38. S. Van Buul-Offers and J. L. Van den Brande. Biosynthetic human growth hormone: effects on growth of Snell dwarf mice. Horm. Metab. Res. 17:20-24 (1986).
39. S. Van Buul-Offers and J. L. Van den Brande. The growth of different organs of normal and dwarfed Snell mice, before and during growth hormone therapy. Acta Endocrinol. 96:46-58 (1981).
40. L. S. Mathews, G. Norstedt, and R. D. Palmiter. Regulation of insulin-like growth factor gene by growth hormone. Proc. Natl. Acad. Sci. U. S. A. 83:9343-9347 (1986).
41. P. Singh. Insuline-like growth factor system in growth, development and carcionegenisis. J. Clin. Ligand Assay 23:214-232 (2000).
42. R. Monzavi and P. Cohen. IGFs and IGFBPs: role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 16:433-447 (2002).
43. M. M. Rechler. Insuline-like growth factor binding proteins. Vitam. Horm. 47:1-114 (1993).
44. T. Laursen, J. O. Jorgensen, and J. S. Christiansen. Metabolic response to growth hormone (GH) administered in a pulsatile, continuous or combined pattern. Endocrinol. Metab. 1:33-40 (1994).
45. V. Tillmann, L. Patel, M. S. Gill, A. J. Whatmore, D. A. Price, M. S. Kibirige, J. K. Wales, and P. E. Clayton. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growtn hormone treatment for disordered growth. Clin. Endocrin. 53:329-336 (2000).
46. P. Park and P. Cohen. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of iodopathic short stature (ISS). Growth Horm. IGF Res. 15:S13-S20 (2005).